Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription

Journal of Virology

Volumn 70, Issue 12, 1996, Pages 8691-8700

  Muralidhar, Sumitra ^a   Doniger, Jay ^a   Mendelson, Elliot ^a   Araujo, John C ^a   Kashanchi, Fatah ^b   Azumi, Norio ^c   Brady, John N ^b   Rosenthal, Leonard J ^a,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CYTOMEGALOVIRUS; DOWN REGULATION; GENE EXPRESSION; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS TRANSCRIPTION;

EID: 0029861282     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.12.8691-8700.1996     Document Type: Article

References (72)

1. Albrecht, T., and F. Rapp. 1973. Malignant transformation of hamster embryo fibroblasts exposure to ultraviolet-irradiated human cytomegalovirus. Virology 55:53-61.
2. Azumi, N., S. T. Traweek, and H. Battifora. 1991. Prostatic acid phosphatase in carcinoid tumors: immunohistochemical and immunoblot studies. Am. J. Surg. Pathol. 15:785-790.
3. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild-type p53 activity. EMBO J. 12:461-468.
4. Boldogh, I., S. Abubaker, and T. Albrecht. 1990. Activation of proto-oncogenes: an immediate early event in cytomegalovirus infection. Science 247: 561-564.
5. Boldogh, I., S. Abubaker, C. Z. Deng, and T. Albrecht. 1991. Transcriptional activation of cellular oncogenes fos. jun, and myc by human cytomegalovirus. J. Virol. 65:1568-1571.
6. Chen, C. Y., J. D. Oliner, Q. Zhan, A. J. J. Fornace, B. Vogelstein, and M. B. Kastan. 1994. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 91:2684-2688.
7. Clanton, D. J., R. J. Jariwalla, C. Kress, and L. J. Rosenthal. 1983. Neoplastic transformation by a cloned human cytomegalovirus DNA fragment uniquely homologous to one of the transforming regions of herpes simplex virus type 2. Proc. Natl. Acad. Sci. USA 80:3826-3830.
8. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not with transformation. Cell 79:817-827.
9. Dutta, A., J. M. Ruppert, J. C. Aster, and E. Winchester. 1993. Inhibition of DNA replication factor RPA by p53. Nature (London) 365:79-82.
10. Dyson, N., P. M. Howley, K. Munger, and E. Harlow. 1989. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937.
11. El-Beik, T., A. Razzaque, R. Jariwalla, R. L. Cihlar, and L. J. Rosenthal. 1986. Multiple transforming regions of human cytomegalovirus DNA. J. Virol. 60:645-652.
12. El-Diery, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
13. Ensoli, B., P. Lusso, F. Schachter, S. F. Josephs, J. Rappaport, F. Negro, R. C. Gallo, and F. Wong-Staal. 1989. Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J. 8:3019-3027.
14. Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:531-539.
15. Foster, S. A., G. W. Demers, B. G. Etscheid, and D. A. Galloway. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:5698-5705.
16. Galloway, D. A., J. A. Nelson, and J. K. McDougall. 1984. Small fragments of herpesvirus DNA with transforming activity contain insertion sequence like structures. Proc. Natl. Acad. Sci. USA 81:4736-4740.
17. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979-9983.
18. Gitlin, S. D., J. Dittmer, R. C. Shin, and J. N. Brady. 1993. Transcriptional activation of the human T-lymphotropic virus type 1 long terminal repeat by functional interaction of Tax1 and ets1. J. Virol. 67:7307-7316.
19. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancer. Science 253:49-53.
20. Inamdar, A., J. Thompson, F. Kashanchi, J. Doniger, J. N. Brady, and L. J. Rosenthal. 1992. Identification of two promoters within human cytomegalovirus morphologic transforming region II. Intervirology 34:146-153.
21. Jahan, N., A. Razzaque, J. N. Brady, and L. J. Rosenthal. 1989. The human cytomegalovirus mtrII colinear region in Tanaka strain is transformation defective. J. Virol. 63:2866-2869.
22. Jariwalla, R. J., A. Razzaque, S. Lawson, and L. J. Rosenthal. 1989. Tumor progression mediated by two cooperating DNA segments of human cytomegalovirus. J. Virol. 63:425-428.
23. Kao, C. C., P. R. Yew, and A. J. Berk. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179:806-814.
24. Kashanchi, F., J. F. Duvall, and J. N. Brady. 1992. Electroporation of viral transactivator proteins into lymphocyte suspension cells. Nucleic Acids Res. 20:4673-4674.
25. Kastan, M. B., Q. Zhan, W. S. El-Diery, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597.
26. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
27. Lane, D. P., and L. V. Crawford. 1979. T-antigen is bound to host protein in SV40 transformed cells. Nature (London) 278:261-263.
28. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus E E1B 55kD protein. Genes Dev. 8:1235-1246.
29. Liu, X., C. W. Miller, P. H. Koeffler, and A. J. Berk. 1993. The p53 activation domain hinds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13:3291-3300.
30. Lo, S. K., K. W. Ip, P. K. Chan, J. M. Nicholls, R. B. Heath, and S. Y. Shiu. 1993. Congenital infection by human cytomegalovirus with a 65 bp deletion in the morphological transforming region II. Arch. Virol. 129:295-299.
31. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (London) 362:847-849.
32. Maheswaran, S., C. Englert, P. Bennett, G. Heinrich, and D. A. Haber. 1995. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9:2143-2156.
33. Malkin, D., F. P. Li, L. C. Strong, J. F. Fraumeni, C. M. Nelson, D. H. Kim, J. Kassel, M. A. Gryka, F. C. Bischoff, M. A. Tainsky, and S. H. Friend. 1990. Germline p53 mutations in familial syndrome of breast cancer, sarcomas and other neoplasias. Science 250:1233-1238.
34. Mansur, C. P., B. Marcus, S. Dalal, and E. J. Androphy. 1995. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457-465.
35. Midgley, C. A., C. J. Fischer, J. Bartek, B. Vojtesek, D. Lane, and D. M. Barnes. 1992. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci. 101:183-189.
36. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
37. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human hax gene. Cell 80:293-299.
38. Muganda, P., O. Mendoza, J. Hernandez, and Q. Qian. 1994. Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. J. Virol. 68:8028-8034.
39. Nelson, J. A., B. Fleckenstein, G. Jahn, D. A. Galloway, and J. K. McDougall. 1984. Structure of the transforming region of human cytomegalovirus AD169. J. Virol. 49:109-115.
40. Nissim, A., H. R. Hoogenboom, I. M. Tomlinson, G. Flynn, C. Midgley, D. Lane, and G. Winter. 1994. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:692-698.
41. Oliner, J. D., J. A. Pietenpol, S. Thiagalinzam, J. Gyures, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (London) 362:857-860.
42. Oren, M., W. Maltzman, and A. J. Levine. 1981. Posttranslational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol. 1:101-110.
43. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193.
44. Ramirez, M. L., M. Virmani, C. Garon, and L. J. Rosenthal. 1979. Defective virions of human cytomegalovirus. Virology 96:311-314.
45. Razzaque, A., N. Jahan, D. McWeeney, R. J. Jariwalla, C. Jones, D. N. Brady, and L. J. Rosenthal. 1988. Localization and sequence analysis of the transforming domain (mtrII) of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 85:5709-5713.
46. Reich, N. C., and A. J. Levine. 1984. Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature (London) 308:199-201.
47. Reid, R. L., P. F. Lindholm, A. Mireskandari, J. Dittmer, and J. N. Brady. 1993. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-1. Oneogene 8:3029-3036.
48. Rogel, A., M. Popliker, C. G. Webb, and M. Oren. 1985. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5:2851-2855.
49. Rosenthal, L. J., and S. Choudhury. 1993. Potential oncogenicity of human cytomegalovirus, p. 412-436. In Y. Becker, G. Darai, and E. S. Huang (ed.), Molecular aspects of human cytomegalovirus diseases. Springer-Verlag, New York.
50. Ruppert, J. M., and B. Stillman. 1993. Analysis of a protein-binding domain of p53. Mol. Cell. Biol. 13:3811-3820.
51. Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus E1B-58kd tumor antigen and SV40 large T antigen are associated with the same 54kd cellular protein in transformed cells. Cell 28:387-394.
52. Schelfner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990 The E6 oncoproteins encoded by the human papillomavirus type 16 and 18 promote the degradation of p53. Cell 63:1129-1136.
53. Schreier, A. A., and J. Gruber. 1990. Viral T antigen interactions with cellular proto-oncogene and anti-oncogene products. J. Natl. Cancer Inst. 582:354-36.
54. Seto, E., A. Usheva, P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028-12032.
55. Smith, M. L., I. T. Chen, Q. Zhan, I. Bae, C. Y. Chen, T. M. Gilmer, M. B. Kastan, P. M. O'Conner, and A. J. J. Fornace. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380.
56. Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952.
57. Speir, E., R. Modali, E.-S. Huang, M. B. Leon, F. Shawl, T. Finkel, and S. E. Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
58. Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757-4762.
59. Thompson, J., J. Doniger, and L. J. Rosenthal. 1994. A 79 amino acid oncogene is responsible for human cytomegalovirus mtrII induced malignant transformation. Arch. Virol. 136:161-172.
60. Thompson, J., A. Inamdar, N. Jahan, J. Doniger, and L. J. Rosenthal. 1993. Localization and sequence analysis of morphological transforming region III within human cytomegalovirus strain Towne. Intervirology 36:121-127.
61. Truant, R., H. Xiao, C. J. Ingles, and J. Greenblatt. 1993. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J. Biol. Chem. 268:2284-2287.
62. Ueda, H., S. J. Ullrich, J. D. Gangemi, C. A. Kappel, and G. Jay. 1995. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet. 9:41-47.
63. Wang, P., M. Reed, Y. Wang, G. Mayr, J. E. Stenger, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: structure, oligomerizalion, and transformation. Mol. Cell. Biol. 14:5182-5191.
64. Wang, S. F., Y. Zhao, Q. L. Fu, M. B. Yin, and Y. Y. Liu. 1987. Detection of cytomegalovirus (CMV) DNA sequence in biopsy samples of cervical cancer. Chung Hua Chung Liu Tsa Chin 9:279-281. (In Chinese.)
65. Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J.-R. Gu, and C. C. Harris. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 91:2230-2234.
66. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
67. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
68. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an antioncogene: the adenovirus E1A proteins hind to the retinoblastoma gene product. Nature (London) 334:124-129.
69. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357: 82-85.
70. Yew, P. R., X. Liu, and A. J. Berk, 1994. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8:190-202.
71. Zantema, A., J. A. M. Fransen, A. Davis-Olivier, F. C. S. Ramaekers, J. B. Voojis, B. Deleys, and A. J. van der Eb. 1985. Localization of the E1b proteins of adenovirus 5 in transformed cells as revealed by interaction with monoclonal antibodies. Virology 142:44-58.
72. zur Hausen, H. 1991. Viruses in human cancer. Science 254:1167-1173.